Pulmonary Edema Following Initiation of Parenteral Prostacyclin Therapy for Pulmonary Arterial Hypertension: A Retrospective Study.
Sign Up to like & getrecommendations! Published in 2019 at "Chest"
DOI: 10.1016/j.chest.2019.02.005
Abstract: BACKGROUND Pulmonary edema may complicate the use of pulmonary arterial hypertension (PAH)-targeted therapies. We aimed to determine the proportion of patients who develop pulmonary edema after initiation of parenteral prostacyclin therapy, to identify its risk… read more here.
Keywords: initiation parenteral; pulmonary arterial; pulmonary edema; edema ... See more keywords
Effects of Parenteral Prostacyclin Therapy on Echocardiographic Variables
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Heart and Lung Transplantation"
DOI: 10.1016/j.healun.2021.01.1290
Abstract: Purpose To evaluate the effects of treating patients with pulmonary arterial hypertension (PAH) with parenteral prostacyclin (IV/SC PGI2) therapy on echocardiographic parameters. Methods We retrospectively assessed echocardiograms of patients diagnosed with PAH by right heart… read more here.
Keywords: therapy; parenteral prostacyclin; prostacyclin therapy; echocardiographic variables ... See more keywords
The effects of parenteral prostacyclin therapy as add-on treatment to oral compounds in Eisenmenger syndrome
Sign Up to like & getrecommendations! Published in 2019 at "European Respiratory Journal"
DOI: 10.1183/13993003.01401-2019
Abstract: Pulmonary arterial hypertension (PAH) develops in 5–10% of patients with congenital heart disease (CHD) [1], and PAH associated with congenital heart disease (PAH-CHD) accounts for a significant proportion of PAH cases (34–42%) [2]. Eisenmenger syndrome… read more here.
Keywords: eisenmenger syndrome; effects parenteral; chd; therapy ... See more keywords